Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 2.36 on Friday. Marinus Pharmaceuticals has a 12-month low of $0.82 and a 12-month high of $2.73. The firm has a 50-day moving average price of $1.67 and a 200-day moving average price of $1.45. The firm’s market cap is $61.54 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. Equities research analysts anticipate that Marinus Pharmaceuticals will post ($0.76) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at

Hedge funds have recently added to or reduced their stakes in the company. Granite Point Capital Management L.P. bought a new stake in Marinus Pharmaceuticals during the first quarter valued at about $1,372,000. Jennison Associates LLC bought a new stake in Marinus Pharmaceuticals during the first quarter valued at about $690,000. Nexthera Capital LP bought a new stake in Marinus Pharmaceuticals during the first quarter valued at about $1,416,000. Finally, KCG Holdings Inc. raised its stake in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 14,692 shares during the last quarter. Institutional investors and hedge funds own 32.70% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.